The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease
- 作者: Mukhin NA1, Milovanov Y.S1, Kozlovskaya LV1, Dobrosmyslov IA1, Milovanova LY.1
-
隶属关系:
- «Первый МГМУ им. И.М. Сеченова»
- 期: 卷 88, 编号 4 (2016)
- 页面: 41-45
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31966
- ID: 31966
如何引用文章
全文:
详细
作者简介
N Mukhin
«Первый МГМУ им. И.М. Сеченова»Москва, Россия
Yu Milovanov
«Первый МГМУ им. И.М. Сеченова»Москва, Россия
L Kozlovskaya
«Первый МГМУ им. И.М. Сеченова»Москва, Россия
I Dobrosmyslov
«Первый МГМУ им. И.М. Сеченова»Москва, Россия
L Milovanova
«Первый МГМУ им. И.М. Сеченова»Москва, Россия
参考
- Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Lee H, Thadhani R, Juppner H, Wold M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Eng J Med. 2008;359(6):584-592. doi: 10.1056/NEJMoa0706130.
- Yilmaz MI, Sonmez A, Saglam M, Yaman HI, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M. and Zoccali C. FGF-23 and vascular dysfunction in atients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010;78:679-685. doi: 10.1038/ki.2010.194.
- Милованова Л.Ю., Милованов Ю.С., Козловская Л.В., Мухин Н.А. Сывороточные уровни морфогенетических белков — фактора роста фибробластов-23 (FGF-23) и Клото (Klotho) при ХБП: клиническое значение. Клиническая нефрология. 2013;2:10-18. doi: 10.2331/susian. 32.804.
- Milovanova L, Milovanov Y, Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III—IV (Systematic Review and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay. INTECH; 2012. doi: 10.1037/0003-066x.59.1.29.
- Милованова Л.Ю., Милованов Ю.С., Крюкова Д.В. Клиническое значение фактора роста фибробластов-23 (FGF-23) и белка Klotho при хронической болезни почек. Клиническая фармакология и терапия. 2013;22(4):1-5. doi:10/ct8vzd.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic Kidney Disease and the risks of death, cardiovascular events, and hospitalization. N Eng J Med. 2004;351(13):1296-1305. doi: 10.1056/NEJMoa041031.
- Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Neveh-Many T, Silver J. The parathyroid is a target organ for FGF-23 in rats. J Clin Invest. 2007;117:4003-4008 doi: 10.1172/JCI32409.
- Maizel J, Six I, Dupont S. Secq E, Dehedin B, Barreto FC, Benchitrit Joyce, Poirot S, Slama M, Tribouilloy C, Choukroun G, Mazière JC, Drueke TB. Massy ZA. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int. 2013;84:491-500. doi: 10.1038/ki.2013.110.
- Craver L, Marco MP, Martinez JM, Rue M, Borras M, Martin ML, Sarro F, Valdivieldso JM, Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22:1171-1176. doi: 10.1093/ndt/gfl718.
- Hu MC, Kuro-o M, Moe OW. Selected Klotho and Chronic Kidney disease. Advanc Exper Med Biol. 2012;728:126-157. doi: 10.1007/978-1-4614-0887-1_9.
- Shimada T, Yamazaki Y, Hasegawa H, Muto T, Hino R, Takeuchi Y, Nakahara K, Fujita T, Fukumoto S, Yamashita T. FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis. J Bon Min Res. 2004;19(4):429-435. doi: 10.1359/JBMR.0301264.
补充文件
